within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA40_Cladribine;

model Cladribine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.37,
    Cl = 6.166666666666667e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.48,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005833333333333333,
    Tlag = 15.0,
    Vdp = 0.19,
    k12 = 9.555555555555555e-06,
    k21 = 9.555555555555555e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cladribine</td></tr><tr><td>ATC code:</td><td>L04AA40</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>480</td><td>L</td></tr>
    <tr><td>clearance:</td><td>22.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cladribine is a purine nucleoside analog used as an antineoplastic and immunosuppressive agent. It is primarily indicated for the treatment of hairy cell leukemia and, more recently, approved for relapsing forms of multiple sclerosis in adults. Cladribine is approved and used in various countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with multiple sclerosis after oral administration of cladribine tablets.</p><h4>References</h4><ol><li><p>Savic, RM, et al., &amp; Karlsson, MO (2017). Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. <i>Clinical pharmacokinetics</i> 56(10) 1245–1253. DOI:<a href=\"https://doi.org/10.1007/s40262-017-0516-6\">10.1007/s40262-017-0516-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28255849/\">https://pubmed.ncbi.nlm.nih.gov/28255849</a></p></li><li><p>Lindemalm, S, et al., &amp; Albertioni, F (2005). Application of population pharmacokinetics to cladribine. <i>BMC pharmacology</i> 5 4–None. DOI:<a href=\"https://doi.org/10.1186/1471-2210-5-4\">10.1186/1471-2210-5-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15757511/\">https://pubmed.ncbi.nlm.nih.gov/15757511</a></p></li><li><p>Meuth, SG, et al., &amp; Hartung, HP (2018). [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]. <i>Der Nervenarzt</i> 89(8) 895–907. DOI:<a href=\"https://doi.org/10.1007/s00115-018-0498-0\">10.1007/s00115-018-0498-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29523912/\">https://pubmed.ncbi.nlm.nih.gov/29523912</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AA40 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cladribine;
